Undertreatment or Overtreatment in the Adjuvant Setting for M1 No Evidence of Disease in Renal Cell Carcinoma: A Clinical Conundrum.

IF 4.8 2区医学 Q1 UROLOGY & NEPHROLOGY

European urology focus Pub Date : 2025-04-17 DOI:10.1016/j.euf.2025.04.009

Wesley Yip, Brian I Rini

引用次数: 0

Abstract

Guidelines recommend consideration of 1 yr of adjuvant pembrolizumab for selected patients with oligometastatic renal cell carcinoma who are disease-free after metastasectomy. Owing to the heterogeneity of this population, it is unclear whether patients would benefit more from single-agent pembrolizumab or from observation and salvage therapy with multiagent regimens. Better prognostic biomarkers are needed to guide treatment decisions in this setting.

查看原文本刊更多论文

肾细胞癌M1无疾病证据的辅助治疗中治疗不足或过度治疗：一个临床难题。

指南建议对转移切除术后无疾病的少转移性肾细胞癌患者考虑1年的辅助派姆单抗治疗。由于该人群的异质性，尚不清楚患者是否从单药派姆单抗中获益更多，还是从多药方案的观察和挽救治疗中获益更多。在这种情况下，需要更好的预后生物标志物来指导治疗决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology focus Medicine-Urology

CiteScore

10.40

自引率

3.70%

发文量

274

审稿时长

23 days

期刊介绍： European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.